Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Blackstone Leads $400 Million Funding Round in Cyera at $9 Billion Valuation 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
BOSTON, Sept. 21, 2016 -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, today announced it will webcast its corporate presentation at the Ladenburg Thalmann 2016 Healthcare Conference on Tuesday, September 27 at 4:00 p.m. Eastern Time.
A live audio webcast of the presentation will be accessible from Keryx’s website at http://investors.keryx.com within the Investor Relations section under “webcasts and presentations.” An archived version of the webcast will be available for at least 15 days following the conclusion of the live presentation.
About Keryx Biopharmaceuticals, Inc.
Keryx Biopharmaceuticals, with headquarters in Boston, is focused on bringing innovative medicines to people with renal disease. In December 2014, the company launched its first FDA-approved medicine, Auryxia® (ferric citrate) in the United States. In January 2014, ferric citrate was approved for use in Japan, where it is being marketed as Riona® by Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex). For more information about Keryx, please visit www.keryx.com.
KERYX BIOPHARMACEUTICALS CONTACT: Lora Pike Senior Director, Investor Relations T: 617-466-3511 [email protected]
